New Investment Opportunity: The EVERY Company
All protein. No animal.
- Sophisticated precision fermentation process replicates alternative egg proteins without chickens, using modified yeast
- First-mover advantage in chicken-free egg market with five-year head start, first product already in market, no established competition
- Outsourcing fermentation to strategic partner AB InBev removes need to invest hundreds of millions of dollars in own facilities
- Heavily oversubscribed $175M Series C round co-led by McWin and Rage Capital
- Strong team with deep industry experience that has formed strategic partnerships
Dear Josb,
The demand for animal-free protein is rapidly growing as consumers seek healthy and sustainable alternatives.
OurCrowd is investing in The EVERY Company, a startup that is the first to produce real egg proteins without chickens. The details in this email are based on information received from, and verified solely by, the company.
The EVERY Company (formerly known as Clara Foods) is disrupting the $200B egg market by replacing chicken-made egg protein.
EVERY is using a technique known as precision fermentation, which uses recombinant DNA techniques to program yeast with chicken genes and feeding the yeast with sugar to create real egg proteins using a process similar to brewing beer. Precision fermentation is the only technology capable of producing real animal proteins affordably and sustainably. Unlike plant-based alternatives, EVERY produces the exact same proteins as those from animals. The company is protecting its IP with 20 patents that have either been granted, applied for, or are in process.
EVERY enjoys a first-mover advantage with a five-year head start over anyone else entering the market to produce animal-free egg protein. There are no established direct competitors as yet.
EVERY has signed a strategic partnership with AB InBev, the world's largest brewer. AB InBev will handle the actual fermentation process, saving hundreds of millions of dollars in capital expense, and giving the company the ability to rapidly scale to high volumes.
EVERY's first product, a digestive enzyme, is in commercial production. The product is already being produced at a profitable cost. The company's second product, a soluble egg protein, is ready for production.
The EVERY Company is led by Arturo Elizondo, who has led EVERY since its inception seven years ago and was included in Forbes' 30 Under 30. CTO Dr. Ranjan Patnaik previously held leadership positions at DuPont and is co-inventor on more than a dozen patents. He holds a doctorate in chemical engineering.
EVERY's $175M Series C round was heavily oversubscribed. The round was co-led by McWin and Rage Capital, an investment fund focused on alternative proteins.
Meet the CEO
We're hosting a webinar/conference call on Tuesday, March 22nd, at 7PM Israel / 1PM New York / 10AM San Francisco for investors to meet CEO Arturo Elizondo and learn more about The EVERY Company.
Can't make the webinar? Register and we will send you a recording of the call.
The EVERY Company Solution
EVERY has one product currently being sold, one ready for sale, and one more in the near-term pipeline.
The company is currently selling a digestive enzyme, which until now was inseparable from the volatile pork supply chain. EVERY's product is a direct 1-to-1 porcine pepsin replacement that is easier on the planet and more effective and consistent. The product is already being produced profitably.
EVERY has a soluble egg protein ready for production. It has a neutral taste and superior optical clarity and application versatility. It will make it feasible to add a protein boost to any hot or cold beverage, whether clear, still, or carbonated.
Also under development is an egg replacer protein which is expected to be a direct replacement for egg whites in many applications from delicate desserts to mixes and patties. The functionality of egg white proteins cannot be matched by plant-based egg substitutes.
Next steps:
0 Comments